Erasca Pivots Strategy, Secures $160M and Licenses Chinese Cancer Drugs Amidst Workforce Restructuring
Erasca, pipeline, workforce reduction, licensing, cancer drugs, China, $160M, strategic shift
FDA Greenlights Amgen’s Innovative T Cell Therapy for Aggressive Lung Cancer
FDA, Amgen, T cell engager, lung cancer, aggressive, AMG 757, bi-specific T cell engager, small cell lung cancer, immunotherapy, cancer treatment, clinical trials.
Pharmaceutical Giants Sanofi, Pfizer, and AstraZeneca Pump $1.87 Billion into French Operations
Sanofi, Pfizer, AstraZeneca, France, investment, pharmaceutical industry, operations, vaccine production, research and development, manufacturing.
CinDome Invests $40 Million in Phase II Clinical Trials for Gastroparesis Treatment
CinDome, gastroparesis, Phase II clinical trials, $40 million investment, medical research, treatment development.
Johnson & Johnson Expands Dermatology Portfolio with $850M Acquisition of Proteologix
Johnson & Johnson, J&J, Proteologix, atopic dermatitis, bispecifics, pipeline, acquisition, $850M
AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals
AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.
Evaluating the Impact of a Dose-Optimization App on Zestril Efficacy for Hypertension Management
Zestril, hypertension, dose-optimization, app, closed-loop testing, efficacy, blood pressure management.
AstraZeneca’s Next-Generation Covid Therapy Shines in Phase 3 Trials
AstraZeneca, Covid-19, Evusheld, Phase 3 trials, next-generation therapy, successor, antibody treatment, prevention, efficacy, safety.
Bristol Myers’ Breyanzi Expands Indications to Include Follicular Lymphoma
Bristol Myers, Breyanzi, CAR-T therapy, follicular lymphoma, FDA approval, cancer treatment, immunotherapy.
Merck KGaA Remains Optimistic About CDMO Business Prospects Amidst Q1 Downturn
Merck KGaA, CDMO, first-quarter, slump, optimism, business prospects, pharmaceutical industry.